Interstitial Lung Diseases in Primary Sjogren's Syndrome
NCT04978883 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 170
Last updated 2021-07-27
Summary
Patients with pSS seen in the Division of Rheumatology, the second affiliated hospital of Zhejiang University, School of Medicine (SAHZU) during January 2016 to July 2018, were retrospectively reviewed. Characteristics were analyzed.
Conditions
- Sjogren's Syndrome
Interventions
- OTHER
-
No intervention
No intervention
Sponsors & Collaborators
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
lead OTHER
Principal Investigators
-
Chen · Second Affiliated Hospital, School of Medicine, Zhejiang University
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-01-01
- Primary Completion
- 2018-07-31
- Completion
- 2018-07-31
More Related Trials
-
Prevalence and Factors of Sarcopenia and in Patients With Primary Sjogren's Syndrome
NCT05015114 ·Status: COMPLETED
-
Immunosuppressant Combined With Pirfenidone in CTD-ILD
NCT04928586 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma
NCT01553981 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Tocilizumab in Primary Sjögren's Syndrome.
NCT01782235 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Echo Systemic Sclerosis
NCT03143413 ·Status: UNKNOWN
-
Utility of Breath-holding Test in Systemic Sclerosis
NCT04484948 ·Status: COMPLETED ·Phase: NA
-
Early Diagnosis of Pulmonary Hypertension in Patients With Inflammatory Rheumatic Connective Tissue Diseases
NCT01387035 ·Status: RECRUITING
-
N-acetylcysteine for Primary Sjögren's Syndrome
NCT04793646 ·Status: COMPLETED ·Phase: NA
-
The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients
NCT04966884 ·Status: UNKNOWN ·Phase: PHASE4
-
Assessment of Serum CD25 Level in Systemic Sclerosis Patients with or Without Interstitial Lung Disease (ILD)
NCT06615128 ·Status: NOT_YET_RECRUITING
-
Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis
NCT02821689 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease
NCT05177471 ·Status: WITHDRAWN
-
Investigation of Respiratory Muscle Sarcopenia in Patients with Systemic Sclerosis
NCT06598982 ·Status: RECRUITING
-
Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension
NCT03459716 ·Status: UNKNOWN
-
Prevalence of Hyperprolactinemia in Systemic Scleroderma
NCT04746313 ·Status: COMPLETED
-
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
NCT02597933 ·Status: COMPLETED ·Phase: PHASE3
-
Patients Diagnosed With Scleroderma: Physical Performance and Functionality
NCT07183072 ·Status: RECRUITING
-
Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome
NCT06688838 ·Status: ENROLLING_BY_INVITATION
-
Penn SICCA Follow-up Study
NCT05056012 ·Status: NOT_YET_RECRUITING
-
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
NCT04837131 ·Status: TERMINATED ·Phase: PHASE2
-
Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance
NCT07182981 ·Status: RECRUITING
-
Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
NCT03509064 ·Status: RECRUITING
-
Implementation of a Biological Sample Collection in Systemic Sclerosis Patients
NCT04986514 ·Status: WITHDRAWN
-
Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease
NCT03856853 ·Status: UNKNOWN ·Phase: PHASE3
-
Clinical Research on Advanced Warning Factors Of Respiratory Injury in Dermatomyositis
NCT04747652 ·Status: UNKNOWN